Form 8-K Revance Therapeutics, For: Nov 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St futures rise on Mideast deal optimism; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Revance Therapeutics (RVNC) Tops Q3 EPS by 20c
November 9, 2015 4:55 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.81), $0.20 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $90 thousand.
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.
... More